-
RemeGen’s Disitamab Vedotin (RC48) Clears for Phase I Study in HER2-Positive Tumors
•
RemeGen Ltd (HKG: 9995), a biopharmaceutical company, has announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a Phase I clinical study for its antibody-drug conjugate (ADC) candidate, disitamab vedotin (RC48). This single-arm, open, single-center study aims to evaluate the safety and maximum tolerable…
-
Junshi Biosciences’ JS401 Receives NMPA Approval for Hyperlipidemia Clinical Trial
•
Junshi Biosciences (HKG: 1877, SHA: 688180), a leading China-based biopharmaceutical company, has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for JS401, an injectable co-developed with Risen Pharma, for the treatment of hyperlipidemia. JS401’s Mechanism of ActionJS401 is an innovative angiopoietin-like 3 (ANGPTL3)…
-
Jiangxi Jemincare Group Secures Exclusive Rights to Promote MabPharm’s Biosimilar CMAB007
•
Jiangxi Jemincare Group, a China-based healthcare company, has entered into a licensing agreement with fellow Chinese firm MabPharm Ltd (HKG: 2181) to obtain exclusive promotion rights to CMAB007, a prospective biosimilar of Roche/Genentech’s anti-IgE drug omalizumab, known under the trade name Xolair. The agreement encompasses rights across Greater China, including…
-
Zhejiang Dian Diagnostics Partners with Meituan for Digital Healthcare Services Expansion
•
Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a prominent medical diagnostics company based in China, has entered into a strategic partnership with Meituan, the country’s leading delivery giant, to explore new digital and intelligent medical and healthcare service models. The collaboration aims to leverage the strengths of both companies to…
-
Ocumension Therapeutics’ Zerviate NDA Accepted for Review by China’s NMPA
•
Ocumension Therapeutics (HKG: 1477), a leading Chinese ophthalmology specialist, has announced that the National Medical Products Administration (NMPA) has accepted for review the New Drug Application (NDA) for Zerviate (OT-1001), a histamine H1 receptor-targeted therapy. This development marks a significant step forward for the company in bringing this innovative treatment…
-
Pfizer and Sinopharm Expand Partnership to Enhance Drug Distribution and Lifecycle Solutions
•
US pharmaceutical giant Pfizer Inc. (NYSE: PFE) has announced a strategic partnership with China-based Sinopharm Group Co., Ltd (HKG: 1099). This collaboration expands on their existing relationship, which spans several years and includes activities in importing, distribution, outsourcing, retailing, and other areas. The partnership aims to leverage Sinopharm’s extensive logistics…
-
Fosun Pharmaceutical’s FCN-159 Earns Breakthrough Therapy Designation for Histiocyte Tumors
•
The Center for Drug Evaluation (CDE) website has announced that Shanghai Fosun Pharmaceutical (Group) Co., Ltd’s (SHA: 600196, HKG: 2196) novel small-molecule chemical drug FCN-159 has been granted breakthrough therapy designation (BTD) status for the treatment of histiocyte tumors. FCN-159’s Mechanism and ImpactFCN-159 is a highly selective MEK1/2 inhibitor with…
-
Aosaikang Pharmaceutical Receives NMPA Review for ASKC200 Liniment from Propella Therapeutics
•
Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) has announced that the National Medical Products Administration (NMPA) has accepted for review its clinical trial approval filing for ASKC200, a liniment product in-licensed from US-based Propella Therapeutics, Inc. The primary indication for the product is the treatment of osteoarthritis pain. Product Rights…
-
HuidaGene Therapeutics Enhances CRISPR-Cas12f System with Higher Editing Efficiency
•
HuidaGene (Shanghai) Therapeutics Co., Ltd, a China-based biotechnology company, has made significant strides in the field of CRISPR-Cas genome editing technology. Through protein and sgRNA engineering, HuidaGene has enhanced the OsCas12f1 (enOsCas12f1) and enRhCas12f1 variants of the CRISPR-Cas12f system. These variants exhibit much higher editing efficiency and possess broader PAMs…
-
Shanghai’s PharmaLegacy Files for IPO on STAR, Targets Pre-clinical R&D Expansion
•
PharmaLegacy Laboratories (Shanghai) Co., Ltd., a Shanghai-based pre-clinical Contract Research Organization (CRO), has reportedly filed for an initial public offering (IPO) with the Shanghai Stock Exchange’s Sci-Tech Innovation Board (STAR). The company anticipates raising RMB 601 million (USD 87.8 million) in proceeds, which will be allocated towards the construction of…
-
Huadong Medicine Reports 9.12% YOY Revenue Growth and 13.24% Increase in Net Profits for 2022
•
Huadong Medicine Co., Ltd (SHE: 000963), a leading China-based pharmaceutical company, has released its 2022 financial report, demonstrating robust growth with revenues of RMB 37.715 billion (USD 5.5 billion), an increase of 9.12% year-on-year (YOY), and net profits of RMB 2.598 billion (USD 379.3 million), marking a 13.24% YOY increase.…
-
BeiGene Launches LATAM Expansion with New Office in São Paulo, Brazil
•
BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235), a China-based biopharmaceutical company, has announced its first major step in expanding its presence in Latin America (LATAM) with the formal opening of its office in São Paulo, Brazil. This strategic move positions BeiGene to tap into the largest oncology market in the…
-
Diapin Therapeutics Announces Breakthrough Preclinical Results for DT-109 in NASH Treatment
•
US-based biotech Diapin Therapeutics has announced groundbreaking results from the latest preclinical tests for its novel oral tripeptide compound, DT-109, which has demonstrated the ability to inhibit the progression of non-alcoholic steatohepatitis (NASH) in monkeys. The study, now published in Cell Metabolism, was conducted by Diapin’s founder Dr. Eugene Chen…
-
Convalife Pharmaceuticals’ Mefuparib Earns Orphan Drug Designation for Cholangiocarcinoma
•
Shanghai-based Convalife Pharmaceuticals has announced that it has received orphan drug designation (ODD) status from the US FDA for its second-generation PARP inhibitor, mefuparib (CVL218). The designation is in recognition of the drug’s potential as a treatment for cholangiocarcinoma, a rare and aggressive form of cancer. Advantages of CVL218 Over…
-
VintaBio Secures $64M Funding to Revolutionize Viral Vectors for Cell and Gene Therapy
•
New biotech VintaBio, founded in Philadelphia, Pennsylvania (United States), announces the appointment of CEO David Radspinner and the securing of USD 64 million in funding led by Decheng Capital. The company, established by scientists Sun Junwei and Dr. Zhou Shangzhen, who were instrumental in the development of the first viral…
-
Alebund Pharmaceuticals Secures $29M in Pre-Series C Funding and $116M Loan for R&D and Manufacturing
•
Shanghai-based Alebund Pharmaceuticals has announced the completion of a pre-Series C financing round worth RMB 200 million (USD 29 million). This funding is supported by a consortium of investors including Yangzhou Guojin Investment, Jiangsu Dingxin Capital, Yangzhou Longchuan Holdings, a leading international sovereign fund, Lilly Asia Ventures, Quan Capital, 3H…
-
Overland ADCT BioPharma Achieves Primary Endpoint in Zynlonta Phase II Study for R/R DLBCL
•
Joint venture Overland ADCT BioPharma (CY) Ltd, a partnership between China’s Overland Pharmaceuticals and Swiss firm ADC Therapeutics SA (NYSE: ADCT), announced that the primary endpoint has been reached in a Phase II regulatory study. The study assessed the efficacy and safety of Zynlonta (loncastuximab tesirine), an antibody-drug conjugate (ADC)…
-
Novartis’ Jakavi Secures NMPA Approval for Acute GVHD Treatment in China
•
Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced that it has received a new indication approval from the National Medical Products Administration (NMPA) for its Janus kinase (JAK) 1/2 inhibitor, Jakavi (ruxolitinib), as a treatment for patients with acute graft versus host disease (acute GVHD). This marks the first approval…
-
Chengdu Hyperway Pharmaceuticals’ HBW-004285 Gets NMPA Tacit Approval for Pain Treatment
•
China-based Chengdu Hyperway Pharmaceuticals has announced receiving tacit clinical trial approval from the National Medical Products Administration (NMPA) for its Nav1.8 inhibitor, HBW-004285, which is intended for the treatment of acute and chronic pain. Understanding the Role of Nav1.8 in Pain SignalingNav1.8 is a tetrodotoxin-insensitive voltage-gated sodium ion channel that…
-
Shanghai Bio-Heart’s Iberis RDN System Meets Primary Endpoint in Iberis-HTN Study
•
Shanghai Bio-Heart Biological Technology Co., Ltd (HKG: 2185) has announced that its Iberis multi-electrode renal radiofrequency denervation (RDN) system has successfully reached its primary clinical endpoint in the randomized, controlled Iberis-HTN study for the treatment of primary hypertension. Iberis-HTN Study ResultsThe prospective, multicenter, blinded, randomized controlled trial was designed to…
